Cala kIQ Plus by Cala Health: status and timeline

Milestones

Next · Commercial expansion and insurance network rollout

Cala kIQ FDA clearance2020Complete.
Medicare coverage approval for essential tremor2024Complete.
Cala kIQ Plus FDA clearance15 Apr 2026Complete.
Trinity Capital $50M growth round20 Apr 2026Complete.
Commercial expansion and insurance network rolloutTarget 2026Current milestone.

Most important updates

Cala Health secures $50M growth capital from Trinity Capital to expand tremor therapy access20 Apr 2026
FDA clears Cala kIQ Plus, next-generation TAPS wearable for essential tremor and Parkinson's hand tremor15 Apr 2026

Upcoming

2026Commercial expansion and insurance network rollout (next)
Q4 2026Expanded insurance coverage negotiation
2027VA reimbursement expansion for Parkinson's tremor

Current obstacles

Limited disease modificationTAPS provides symptom relief but does not modify underlying disease progression; patients must continue other therapies.
Patient compliance and device comfortLong-term daily wearability and comfort are key to retention; wrist discomfort during extended use remains a minor reported issue.

Physics limits

Electrode contact variabilityWrist anatomy and skin conductivity vary per patient, requiring calibration tuning. Proper electrode placement is critical for efficacy.
Peripheral nerve plasticityChronic stimulation may trigger adaptive changes in peripheral nerves over months to years; long-term tolerance is still being studied.

How it works

3 parts

Neural sensing

Detects nerve activity

Electrodes in the wristband measure electrical signals from peripheral nerves controlling hand muscles.

Pattern generation

Creates therapeutic pulse patterns

Device generates patterns mimicking healthy nerve activity, calibrated to each patient's response.

Tremor suppression

Blocks tremor signals

Patterned stimulation suppresses abnormal signals causing tremors, without affecting voluntary movement.

Spec sheet

Spec	Cala kIQ Plus
Device form factor	Wrist-worn wearable^R (reported)
Tremor improvement (263 patients)	62% to mild; 54% ≥50% reduction^R (reported)
Therapy modes (kIQ Plus)	Three modes with adaptive calibration^R (reported)

^R reported by the company

Update log

2 updates

Mon 20 Apr

Major: Cala Health secures $50M growth capital from Trinity Capital to expand tremor therapy accessPressFunding

Wed 15 Apr

Major: FDA clears Cala kIQ Plus, next-generation TAPS wearable for essential tremor and Parkinson's hand tremorRegulatorRegulatory

About Cala Health

The team behind Cala kIQ Plus

Cala Health

Wearable nerve stimulation, tremor relief

Cala Health develops wearable bioelectronic medicine for hand tremors. The kIQ Plus delivers personalized nerve stimulation via a wrist-worn device and is expanding access through insurance.

kIQ Plus uses electrical nerve stimulation for tremor relief in essential tremor and Parkinson's patients.
263-patient study: 62% improved tremor severity in 3 months; 54% achieved ≥50% tremor reduction.
Trinity Capital committed $50M growth capital in April 2026 to scale commercial expansion.

calahealth.com (opens calahealth.com)Company profile →

Founded: 201412 yrs
Headquarters: United States
Status: Private
Valuation: private
Works in: NeurotechNerve & muscle interfaces
Coverage: 1 program · 2 updateslatest 20 Apr 2026checked 11 Oct
Investors: Trinity Capital
People: Kate RosenbluthCo-founder, Chief Scientific OfficerScott DelpCo-founderSerena WongCo-founder

Spec

Cala kIQ Plus

Device form factor

Wrist-worn wearable^R (reported)

Tremor improvement (263 patients)

62% to mild; 54% ≥50% reduction^R (reported)

Therapy modes (kIQ Plus)

Three modes with adaptive calibration^R (reported)